ESTRO 2024 - Abstract Book

S2548

Clinical - Urology

ESTRO 2024

Conclusion:

In this group of prostate cancer patients treated with SMART, a 5-year local control rate was achieved of 84%, despite almost two thirds of patients belong to high risk group for biochemical recurrence. Predictors for recurrence were perineural growth, intraductal carcinoma, bilateral tumor, Gleason score and T stage.

Keywords: Prostate cancer, SMART, MR-guided radiotherapy

References:

1. Kishan AU, Ma TM, Lamb JM, et al; Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol. 2023 Mar 1;9(3):365-373. doi: 10.1001/jamaoncol.2022.6558. 2. Tetar SU, Bruynzeel AME, Oei SS, et al; Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. Eur Urol Oncol. 2021 Aug;4(4):628-634. doi: 10.1016/j.euo.2020.05.007.

2549

Digital Poster

Prostate radiotherapy with rectal spacer in patients with bowel comorbidities - one year on.